id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-337444-pqoq8aew	Doi, Kent	Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series	2020-07-03		.txt	text/plain	988	55	43	title: Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series Through high-throughput screening of 1017 existing drugs, a clinically available serine protease inhibitor nafamostat mesylate was identified as a potent inhibitor of Middle East respiratory syndrome coronavirus entry into human epithelial cells [2] . Eleven adults with reverse transcriptase polymerase chain reaction-confirmed SARS-CoV-2 infection were admitted to the intensive care unit (ICU) at The University of Tokyo Hospital between April 6 and April 21, 2020, and treated with nafamostat mesylate in combination with favipiravir. Although the number of patients in this case series was very small, this low mortality rate suggests that combination treatment of favipiravir and nafamostat mesylate may be effective for critically ill Covid-19 patients. A clinical trial for the combination treatment of nafamostat mesylate and favipiravir against Covid-19 will be initiated in Japan (jRCTs031200026). Nafamostat mesylate blocks activation of SARS-CoV-2: new treatment option for COVID-19	./cache/cord-337444-pqoq8aew.txt	./txt/cord-337444-pqoq8aew.txt